Richard Cunningham
Chief Executive Officer bei ANEBULO PHARMACEUTICALS, INC.
Profil
Richard Anthony Cunningham currently works at Icagen-T, Inc., as President, Chief Executive Officer & Director and Anebulo Pharmaceuticals, Inc., as Chief Executive Officer & Director from 2023.
Mr. Cunningham also formerly worked at Icagen, Inc., as President, Chief Executive Officer & Director in 2020 and Tyme Technologies, Inc., as Chief Executive Officer & Director from 2020 to 2022.
Aktive Positionen von Richard Cunningham
| Unternehmen | Position | Beginn |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Chief Executive Officer | 05.10.2023 |
Icagen-T, Inc.
 Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Richard Cunningham
| Unternehmen | Position | Ende |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Chief Executive Officer | 16.09.2022 |
Icagen, Inc.
 Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Chief Executive Officer | 01.11.2020 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Icagen, Inc.
Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Icagen-T, Inc.
Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Health Technology |
